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Proform serum calcium-decreasing factor (procaldecrin) was purified from porcine pancreas acetone powder. Procaldecrin showed chymotrypsin 
activity after trypsin treatment in a time- and dose-dependent manner. Procaldecrin did not possess erum calcium-decreasing activity but acquired 
serum calciumdecreasing activity as well as protease activity after trypsin treatment. However, PMSF treatment after activation of procaldecrin 
by trypsin did not atTect the serum calcium-decreasing activity, even though protease activity was nullified by treatment with PMSF. These findings 
suggest hat the serum calcium-decreasing activity acquired by procaldecrin requires conformational change caused by trypsin treatment. 
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1. INTRODUCTION 
Acute pancreatitis causes hypocalcemia, which sug- 
gests that pancreas tissue contains the serum calcium- 
decreasing factor [l]. Yoneda et al. reported the hy- 
pocalcemic factor in porcine pancreas [2]. We have re- 
ported the isolation and characterization of the serum 
calcium-decreasing factor (caldecrin) from porcine pan- 
creas and that it is chymotrypsin-type serine protease 
[31* 
The mammalian exocrine pancreas synthesizes, 
stores, and secretes proteins, in which the dominant 
fraction is the family of serine proteases [4]. The serine 
proteases are synthesized initially as precursor proteins 
(preproenzyme) for secretory proteins [5,6] and are se- 
creted as proenzymes (zymogens) that require enzy- 
matic cleavage of an amino terminus for conversion to 
active enzymes. 
Thus, it is suggested that caldecrin exists in pancreas 
tissue as a proform. If so, it is of interest to know 
whether proform caldecrin possesses erum calcium-de- 
creasing activity, and whether the mechanism for acti- 
vation of the proform concerns the regulation of serum 
calcium-decreasing activity. 
*Corresponding author. Fax: (8 1) (992) 64-6274. 
Abbreviations: caldecrin, serum calcium-decreasing factor; DFP, 
diisopropyl fluorophosphate; PMSF, phenyhnethylsulphonyl fluo- 
ride; APMSF, (4-amidino-phenyl)methane-sulphonyl fluoride; Suc- 
Ala-Ala-Pro-Phe-pNA, succinyl-L-alanyl-L-alanyl-r.-prolyl-L-phenyla- 
lanine p-nitroanilide. 
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Activation of procaldecrin to caldecrin is essential for 
the acquisition of serum calcium-decreasing activity, 
but protease activity after activation is not necessary. 
2. EXPERIMENTAL 
2.1. Materials 
Sue-Ala-Ala-Pro-Phe-pNA was purchased from the Peptide Insti- 
tute, Inc. (Osaka, Japan). DFP, PMSF, APMSF and trypsin were 
obtained from Sigma Chemical Co. (ST. Louis, USA). Porcine pan- 
creas acetone powder was prepared from fresh pancreas tissues [7]. 
2.2. Assay of procaldecrin 
Procaldecrin was detected by enzyme-linked immuno assay 
(ELISA) using anti-caldecrin antibody as described previously [3] and 
by the acquisition of chymotrypsin activity after trypsin activation 
done as described below. Chymotrypsin activity was measured using 
a synthetic substrate, Sue-Ala-Ala-Pro-Phe-pNA [8]. 
2.3. Purification of proform caldecrin from porcine pancreas acetone 
powder 
Acetone powder of porcine pancreas was extracted with 10 mM 
T&-acetate buffer (pH 6.0) containing 1 mM DFP at 4°C for 1 h. 
After centrifugation, the supernatant was diluted with homogenizing 
buffer, and combined with DE-23 ion-exchange cellulose (Pharmacia). 
After gentle mixing for 2 h, the cellulose was packed on the column 
(2.7 x 8.7 cm), washed with the same buffer, and then the absorbed 
materials were eluted by a gradient of NaCl from 0 to 0.4 M in the 
starting buffer at a flow rate of 4.9 ml/min, and 9.2 ml fraction was 
collected. The fractions of proform caldecrin were combined and re- 
ceived saturated ammonium sulfate to 20%, and were then applied to 
a Toyo-pearl hydrophobic column (Tosoh, Japan). The absorbed ma- 
terials were eluted by a gradient of ammonium sulfate from 20% to 
0 in 30 mM sodium citrate buffer (pH 6.0) at a flow rate of 1.85 ml/min, 
and 3 ml fraction was collected. The third peak was collected, received 
ammonium sulfate and reapplied to a small hydrophobic column. 
Proform caldecrin was eluted with a small volume of sodium citrate 
buffer to concentrate, and then applied to a Sephadex G-100 (Pharma- 
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cia) gel filtration column (3 x 95 cm) equilibrated with 30 mM sodium 
citrate buffer (PH 6.0). The fractions (5.7 ml per tube) were collected 
at a ffow rate of 46 ml/h. The second peak was collected for proform 
caldecrin. 
2.4. lime course of activation of procaldecrin by trypsin activation 
Proform caldecrin (1.5 pg) was activated by incubation with trypsin 
at varied procaldecrin-trypsin ratios (mol:mol) for varied times at 4°C 
and the reaction was stopped by addition of 1 mM APMSF. Activated 
caldecrin was detected by acquisition of chymotrypsin activity for 0.1 
mM Sue-~a-Ala-Pro-Phe-pea as a substrate. 
2.5. Serum calcium-decreasing activity of procaldecrin 
Procaldecrin was activated at 4°C for 60 min by trypsin at ratios 
of 1:lOO and 2:100. Caldecrin and activated procaldecrin were incu- 
bated with and without 1 mM PMSF for 10 min at room temperature, 
and then the buffer was changed by the centrifuged-column procedure 
[9] with Sephadex G-50 column calibrate with phosphate buffered 
saline (PBS), The eluted samples were diluted to a final concentration 
of 80 ,ug/ml with PBS. One hundred@ of the final sample per 20 g body 
weight of mouse was injected via mouse tail vein and serum calcium 
was assayed as described before [3]. 
2.6. Other methods 
SDS-PAGE and Western blotting analysis were performed as de- 
scribed previously [3]. 
3. RESULTS AND DISCUSSION 
Proform of porcine pancreas caldecrin (procaldecrin) 
was purified from homogenate of porcine pancreas ace- 
tone powder with 1 mM DFP by a combination of 
anion-exchange, hydrophobic interaction, and gel filtra- 
tion chromatography with a yield of 5.7 mg of protein 
per 25 g of pancreas acetone powder. 
Fractions containing procaldecrin were detected by 
ELISA and by the ch~ot~s~ assay after trypsin 
activation (see below). Fractions from each step of the 
purification were analyzed by SDS-PAGE (Fig. 1A) 
followed by Western blot analysis using antiserum for 
porcine caldecrin (Fig. 1B) as described previously [3]. 
A) SDS-PAGE (reduced) 
67K-+ 
30K-m-- 
ZOK-BD- 
14K-+ 
2.5K-w 
Procaldecrin with a molecular weight of 30 kDa was 
immunoreacted with the anti-caldecrin antibody. 
Next, we performed activation of purified procalde- 
crin by trypsin at varied ratios of trypsin to procaldecrin 
(Fig. 2A). The higher mol ratio of trypsin to procalde- 
crin caused rapid activation of procaldecrin and gave 
rise to maximum chymotrypsin activity within 5 min but 
later caused a slight decrease in the activity. Maximum 
activation was obtained by 60 min incubation at all 
ratios except the lowest ratio at 1:lOO. Procaldecrin ac- 
tivated by trypsin at the varied ratios for 60 min was 
analyzed by SDS-PAGE (Fig. 2B). The low treatment 
ratio (trypsin-procaldecrin ratio 1: 100) caused partial 
conversion of pro to active caldecrin as indicated by 
double bands around 30 kDa, which corresponds to 
chymotrypsin activity (Fig. 2A and 2B, see 1:lOO treat- 
ment ratio). The higher treatment-ratio of trypsin to 
procaldecrin showed complete conversion of proform 
to activated caldecrin, which was also indicated by chy- 
motrypsin activity (Fig. 2A and 2B). These results sug- 
gest an apparently direct or one-step conversion of pro- 
caldecrin into activated caldecrin by trypsin treatment, 
and also suggest hat the difference in molecular weight 
between procaldecrin (about 30 kDa) and activated cal- 
decrin (about 28 kDa) was consistent with the removal 
of the activation peptide segment from the zymogen to 
its mature form. 
We next investigated whether the activation of pro- 
caldecrin is related to the serum calcium-decreasing ac- 
tivity. As shown in Fig. 3, chymotrypsin activities of 
procaldecrin and procaldecrin activated by treatment 
with trypsin (1:lOO and 2: 100) were compared with 
serum c~ci~d~reas~g activity. Procaldecrin pos- 
sessed very low chymotrypsin activity and did not show 
serum calcium-decreasing activity. Trypsin treatment at 
1:lOO partially activated the chymotrypsin activity of 
procaldecrin to 7 times over basal activity, and serum 
Bf Western blot 
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Fig. 1. (A) SDS-PAGE and (B) Western blotting analysis of procaldecrin during its purification steps for homogenate (lane 1,32 ,ug), ion-exchange 
calm eluate (lane 2,25 pg), hydrophobic column eluate (lane 3,19 pg), gel filtration calm (lane 4,9.4 @g) and porcine purified caldecrin (lane 
5, 6.9 pg). The protein content of each lane of Western blotting analysis was half of that of SDS-PAGE. 
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Fig. 2. Time course of activation of procaldecrin by trypsin. (A) chymotrypsin activity was determined by hydrolysis of Sue-Ala-Ala-Pro-Phe-pNA. 
Procaldecrin was incubated with various ratios of trypsin for the indicated time at 4°C. Values are means of duplicate measurements. (B) SDS-PAGE 
(2.5 pug) per lane was used from the sample used for chymotrypsin activity at 60 min incubation. 
calcium-decreasing activity also appeared (5.8% de- 
crease from control serum calcium level). Treatment of 
PMSF after trypsin-activated procaldecrin destroyed 
chymotrypsin activity but retained the serum calcium- 
decreasing activity. In this assay, the trypsin used for 
procaldecrin activation was contaminated with procal- 
decrin. However, trypsin at the same dose as caldecrin 
did not show any serum calcium-decreasing activity [3]. 
Trypsin treatment of procaldecrin (2:lOO) caused full 
activation of chymotrypsin activity and serum calcium- 
decreasing activity comparable with the activities of pu- 
rified active caldecrin. PMSF treatment o the fully acti- 
vated procaldecrin by trypsin (2: 100) and purified active 
caldecrin diminished the chymotrypsin activity but had 
no effect on the serum calcium-decreasing activity. 
These results suggest hat the activation of the chymo- 
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Fig. 3. Comparison of the chymotrypsin activity and the serum cal- 
cium-decreasing activity of procaldecrin and trypsin activated procal- 
decrin. One unit (U) of chymotrypsin activity indicates an increase of 
absorbance at 415 nm by 5 min incubation with substrate at 25’C. The 
chymotrypsin activity and serum calcium-decreasing activity are 
means + S.D. of triplicate measurements and of five mice, respectively. 
trypsin activity of procaldecrin by trypsin is necessary 
for the acquisition of the serum calcium-decreasing ac- 
tivity, but that the chymotrypsin activity after activa- 
tion of procaldecrin is not necessary for the serum cal- 
cium-decreasing activity. Conformational change of 
procaldecrin by trypsin treatment may be essential for 
the serum calcium-decreasing activity. 
It is of great interest to know the mechanism of ex- 
pression of serum calcium-decreasing activity from in- 
active procaldecrin. Recently, Arita et al. reported that 
mammalian secretory pancreatic phospholipase A, not 
only catalyzes the hydrolysis of phospholipids but also 
elicits a variety of biological responses in mammalian 
cells which have the specific receptor [lo]. The enzy- 
matically inactive precursor of phospholipase AZ could 
not have receptor-binding capacity even though the 
structure of the precursor is almost the same as that of 
the mature form and the receptor-binding capacity of 
the mature form is separable from its enzyme activity 
[11,12]. 
Therefore, our present results showing that pancre- 
atic procaldecrin acquires the serum calcium-decreasing 
activity by trypsin activation are highly homologous to 
the activation and bioactivity of pancreas phospholip- 
ase A,. 
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